Caire, which operates under Chart’s BioMedical segment, has completed the previously announced acquisition of Covidien’s oxygen therapy business, including the design, manufacturing, and sales and service functions worldwide.
Reportedly, the acquisition includes products sold under the Companion and HELiOS brands. Financial terms of the transaction were not disclosed.
Steve Shaw, president of Chart BioMedical Group, said: “We are pleased to have the Companion and HELiOS liquid oxygen therapy brands included in our product offering and look forward to selling and servicing these products under Caire. As previously mentioned, we expect to complete the integration of this business into Caire towards the end of 2010.”
Earlier in September, 2009, Chart had reported that its wholly-owned subsidiary, Caire, which operates under its BioMedical segment, has entered into a definitive agreement with Covidien to acquire their oxygen therapy products, including the design, manufacturing, and sales and service functions worldwide.